4-甲氧基苯乙酰氯 | 4693-91-8

• 物质功能分类: 化学试剂 - 有机试剂 - 酰卤
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-甲氧基苯乙酰氯
• 中文别名: 4-甲氧基苯基乙酰基氯；4-甲氧基苯基乙酰氯
• 英文名称: 4-Methoxyphenylacetyl chloride
• 英文别名: 4-methoxyphenyl-acetic chloride；2-(4-methoxyphenyl)acetyl chloride；p-methoxyphenylacetyl chloride
• CAS: 4693-91-8
• 化学式: C₉H₉ClO₂
• 分子量: 184.622
• InChiKey: CXJOONIFSVSFAD-UHFFFAOYSA-N

物化性质

• 沸点：
  143 °C10 mm Hg(lit.)
• 密度：
  1.208 g/mL at 25 °C(lit.)
• 闪点：
  >230 °F
• 稳定性/保质期：

  在常温常压下保持稳定

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  8
• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R34
• WGK Germany：
  3
• 海关编码：
  29189900
• 包装等级：
  II
• 危险类别：
  8
• 危险品运输编号：
  UN 3265 8/PG 2
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H314
• 储存条件：
  请将产品存放在2-8℃的通风干燥处，并密封保存。

SDS

Name:	4-Methoxyphenylacetyl chloride Material Safety Data Sheet
Synonym:	None Known
CAS:	4693-91-8

Section 1 - Chemical Product MSDS Name:4-Methoxyphenylacetyl chloride Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
4693-91-8	4-Methoxyphenylacetyl chloride	ca. 100	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye burns. Lachrymator (substance which increases the flow of tears).
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Chronic exposure may cause effects similar to those of acute exposure.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately. Do NOT allow victim to rub eyes or keep eyes closed.
Skin:
In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical aid immediately. Wash clothing before reuse.
Ingestion:
If swallowed, do NOT induce vomiting. Get medical aid immediately.
If victim is fully conscious, give a cupful of water. Never give anything by mouth to an unconscious person.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Will burn if involved in a fire. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide. Do NOT get water inside containers.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation. Do not get water inside containers.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Keep container tightly closed. Do not ingest or inhale. Use only in a chemical fume hood. Discard contaminated shoes.
Keep from contact with moist air and steam.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Store protected from moisture. Store under nitrogen.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 4693-91-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 143 deg C @10mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: > 110 deg C (> 230.00 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density: 1.208
Molecular Formula: C9H9ClO2
Molecular Weight: 184.62

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Moisture sensitive.
Conditions to Avoid:
Exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 4693-91-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Methoxyphenylacetyl chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: Pseudomonas putida:

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3265
Packing Group: II
IMO
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3265
Packing Group: II
RID/ADR
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3265
Packing group: II

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 4693-91-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 4693-91-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 4693-91-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用

4-甲氧基苯乙酰氯是一种有机合成中间体和医药中间体，可应用于实验室研发过程以及化工生产中。

反应信息

• 作为反应物：
  描述：

  4-甲氧基苯乙酰氯 在 sodium carbonate 、 三氯氧磷 作用下， 以 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 4.0h， 生成 6,7-dimethoxy-1-(4-methoxybenzyl)-3,4-dihydroisoquinoline
  参考文献：
  名称：

  可见光介导的双氧氧化 1-苄基-3,4-二氢异喹啉：1-苯甲酰基异喹啉和 1-苯甲酰基-3,4-二氢异喹啉的可转换合成

  摘要：

  可见光介导的 1-苄基-3,4-二氢异喹啉 (1-BnDHIQs) 的无金属氧化，用于可切换制备多种 1-苯甲酰基异喹啉 (BzIQs) 和 1-苯甲酰基-3,4-二氢异喹啉(BzDHIQs) 是使用双氧作为氧化剂实现的。该方案为高效合成异喹啉生物碱提供了一条简便的途径。机理研究表明自由基途径和离子途径可能同时存在，这两种途径都通过共同的关键过氧化物中间体进行，产生氧化产物。

  DOI：

  10.1055/a-2160-8903
• 作为产物：
  描述：

  对甲氧基苯乙酸 在 氯化亚砜 作用下， 以95%的产率得到4-甲氧基苯乙酰氯
  参考文献：
  名称：

  Synthesis, Selective Aldose Reductase Inhibitory Profile and Antihyperglycaemic Potential of Certain Parabanic Acid Derivatives

  摘要：

  描述了某些对二氨基甲酸衍生物1a-p的合成和醛糖还原酶抑制剖面。此外，研究了这些化合物的抗高血糖潜力。在这个系列中，最活跃的抑制剂是化合物1g、1p和10，它们在浓度为1 x 10−4时分别显示出36.6%、90%和91%的抑制活性。它们的IC50分别为2 x 10−6、7.5 x 10-8和5 x 10-8。化合物10表现出明显的抗高血糖效果。

  DOI：

  10.3797/scipharm.aut-01-204
• 作为试剂：
  描述：

  对甲氧基苯乙酸 、 2-bromo-6-hydroxyimino-8,9-dihydro-7H-benzo[7]annulen-5-one 在 4-甲氧基苯乙酸酐 、 4-甲氧基苯乙酰氯 作用下， 以53%的产率得到
  参考文献：
  名称：

  Design and optimization of tricyclic gamma-secretase modulators

  摘要：

  Beginning with a diaminotriazine screening hit, several series of novel, tricyclic gamma-secretase modulators (GSMs) were designed. The SAR of several related series of GSMs is presented, and the in vivo profile of a lead molecule from the series is described. (C) 2016 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2015.06.020

文献信息

• Directed Remote Lateral Metalation: Highly Substituted 2-Naphthols and BINOLs by In Situ Generation of a Directing Group
  作者：Jignesh J. Patel、Marju Laars、Wei Gan、Johnathan Board、Matthew O. Kitching、Victor Snieckus

  DOI：10.1002/anie.201805203

  日期：2018.7.20

  general synthesis of highly substituted 2‐naphthols based on a new carbanionic reaction sequence is demonstrated. The reaction exploits the dual nature of lithium bases consisting of consecutive ring opening of readily available coumarins with either LiNEt2 or LiNiPr2 into Z‐cinnamamides, thus generating a directing group in situ and allowing, by conformational freedom, a lateral directed remote metalation

  演示了基于新的碳负离子反应序列的高度取代的2-萘酚的一般合成。该反应利用了锂碱的双重性质，即将容易获得的具有LiNEt 2或LiN i Pr 2的香豆素连续开环成Z肉桂酰胺，从而在原位生成一个导向基团，并通过构象自由度允许横向定向的远程金属化以进行闭环反应，得到芳基2-萘酚，收率好至极好。可以将这些转换组合起来，以提供更有效的单锅法。对远端横向金属化步骤的机械洞察力，证明了对Z的要求描述了肉桂酰胺。还报道了该方法在高度取代的3,3'-二芳基BINOL配体合成中的应用。
• [EN] INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING<br/>[FR] INHIBITEURS DE LA LIAISON PROTÉINE WDR5-PROTÉINE
  申请人：ONTARIO INST FOR CANCER RES (OICR)

  公开号：WO2017147700A1

  公开（公告）日：2017-09-08

  The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

  本申请涉及到Formula I的化合物：包括这些化合物的化合物及其用途，例如作为治疗由于抑制WDR5蛋白与其结合伙伴之间结合而介导或可治疗的疾病、疾病或症状的药物。
• Thienopyridone derivatives useful as activators of AMPK
  申请人：Poxel

  公开号：EP2679591A1

  公开（公告）日：2014-01-01

  The invention relates to compounds that are direct activators of AMPK (AMP-activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, liver disease, hepatic steatosis, non alcoholic fatty liver disease (NAFLD), non alcoholic steato-hepatitis (NASH), liver fibrosis, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, inflammation, cancer, cardiovascular diseases, atherosclerosis, high blood pressure, retinopathies or neuropathies.

  该发明涉及直接激活AMPK（AMP-激活蛋白激酶）的化合物及其在治疗受AMPK激活调节的疾病中的应用。例如，根据该发明的化合物对于治疗糖尿病、代谢综合征、肥胖、肝病、肝脂肪变性、非酒精性脂肪肝病（NAFLD）、非酒精性脂肪肝炎（NASH）、肝纤维化、血脂异常、高三酰甘油血症、高胆固醇血症、炎症、癌症、心血管疾病、动脉粥样硬化、高血压、视网膜病变或神经病变方面具有用处。
• Macrocyclic compounds as inhibitors of viral replication
  申请人：Blatt M. Lawrence

  公开号：US20050267018A1

  公开（公告）日：2005-12-01

  The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  该实施例提供了一般式I-XIX的化合物，以及包括药物组合在内的组合物，其中包括一种主体化合物。该实施例还提供了治疗方法，包括治疗黄病毒感染的方法，包括丙型肝炎病毒感染的方法和治疗肝纤维化的方法，这些方法通常涉及向需要的个体施用一种主体化合物或组合物的有效量。
• Design, Synthesis, and Biological Evaluation of New 8-Heterocyclic Xanthine Derivatives as Highly Potent and Selective Human A_2B Adenosine Receptor Antagonists
  作者：Pier Giovanni Baraldi、Mojgan Aghazadeh Tabrizi、Delia Preti、Andrea Bovero、Romeo Romagnoli、Francesca Fruttarolo、Naser Abdel Zaid、Allan R. Moorman、Katia Varani、Stefania Gessi、Stefania Merighi、Pier Andrea Borea

  DOI：10.1021/jm0309654

  日期：2004.3.1

  in radioligand binding assays at human (h) A(1), A(2A), A(2B), and A(3) ARs. We introduced several heterocycles, such as pyrazole, isoxazole, pyridine, and pyridazine, at the 8-position of the xanthine nucleus and we have also investigated different spacers (substituted acetamide, oxyacetamide, and urea moieties) on the heterocycle introduced. Various groups at the 3- and 4-positions of phenylacetamide

  在这里，我们报告8杂环取代的黄嘌呤作为有效和选择性A（2B）腺苷受体拮抗剂的合成。探索了黄嘌呤与重组人A（2B）腺苷受体（ARs）结合在HEK-293细胞（HEK-A（2B））和其他AR亚型中的结构活性关系（SAR）。合成的化合物在纳摩尔浓度范围内显示出A（2B）腺苷受体亲和力，并且在人类（h）A（1），A（2A），A（2B）和A（3）的放射性配体结合测定中评估了良好的选择性水平AR。我们在黄嘌呤核的8位引入了几个杂环，例如吡唑，异恶唑，吡啶和哒嗪，我们还研究了所引入杂环上的不同间隔基（取代的乙酰胺，氧乙酰胺和脲部分）。研究了苯基乙酰胺部分的3位和4位上的各种基团。这项研究使我们能够确定衍生物2-（3,4-二甲氧基苯基）-N- [5-（2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin- 8-基）-1-甲基-1H-吡唑-3-基]乙酰胺（29